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6 Abstract 
ABSTRACT
Preclinical evaluation of common markers and iohexol for the development of intestinal 
permeability tests in dogs. — Studies on laboratory Beagle dogs and Sprague-Dawley rats.
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University 
of Helsinki, Finland.
Intestinal permeability testing is the specific method to assess for a defective intestinal epithelial 
barrier. Intestinal permeability measurements are considered helpful and non-invasive means to 
evaluate intestinal mucosal damage for both scientific (particularly) and clinical purposes, and have 
been widely used in laboratory rodents and humans. Despite their many advantages, permeability 
tests have not gained widespread use as a testing option for the detection and management of canine 
intestinal disorders in veterinary clinical research. The main reasons for this may include the lack of an 
optimal biomarker for permeability testing, impracticalities involving current testing methodologies, 
and inconsistencies in test results that have been found by investigators using these tests. 
Chromium 51-labeled ethylenediamine tetra-acetic acid (51Cr-EDTA) is widely considered the 
most accurate intestinal permeability probe, but the use of radioactivity is a major drawback. 
Sugar biomarkers such as lactulose and rhamnose have been more commonly used in the recent 
years, but they have been associated with marked inconsistencies in the test results. Iohexol is a 
contrast medium commonly used in radiology for diagnostic purposes in human and veterinary 
patients, but this molecule has more recently been successfully used for the screening of gut 
mucosal damage in laboratory rats and humans. The main advantage of iohexol is that its use 
does not involve radioactivity, nor is it degraded in the intestinal lumen. Furthermore, it has the 
potential to be quantified by different analytical techniques. 
The main objective of this project was to improve the methodology of the intestinal permeability 
tests in dogs in order to make the testing simpler, more practical and accurate for veterinarians and 
researchers using this approach to investigate intestinal mucosal damage and disorders associated with 
a defective intestinal epithelial barrier. An additional objective was to preliminarily assess the use of 
iohexol as a novel intestinal permeability marker for use in dogs. The work consisted of preclinical 
comparisons of the most relevant intestinal permeability markers including 51Cr-EDTA, lactulose and 
rhamnose, and iohexol performed in both urine and blood tests using laboratory dog and rat models.  
In conclusion, studies on the percentage urinary recovery of 51Cr-EDTA, lactulose, and rhamnose, as 
well as D-xylose, 3-O-methyl-D-glucose, and sucrose after their oral simultaneous administration 
provided normative data for healthy adult male Beagle dogs. The analysis revealed a discrepancy 
in the percentage urinary recovery between 51Cr-EDTA and lactulose, suggesting that these two 
markers are not as equivalent as has so far been believed based on previous studies in humans and 
cats. It was also concluded that the use of a single marker provides comparable test results to the use 
of two markers, as evidenced by a comparison of recovery values from 51Cr-EDTA and lactulose 
versus their correspondent ratio against rhamnose. This supports the hypothesis that, in contrast to 
the dual sugar test, the use of one inert larger probe may be sufficient for permeability testing, and 
the testing procedure may consequently be considerably simplified. The studies also demonstrated 
that the 51Cr-EDTA permeability blood test based on the collection of at least two serum or plasma 
specimens gives comparable results to the 6-h cumulative urine test. The blood approach is much 
easier than the urine-based test, as it avoids the constraints associated with urine collection in 
dogs. Iohexol was shown to have a clear relationship with 51Cr-EDTA in serum levels when they 
were simultaneously administered to Beagle dogs. When it was used as an intestinal permeability 
probe in laboratory rats before and after the induction of a well-characterized experimental form of 
inflammatory bowel disease, it was also possible to clearly discriminate between healthy animals and 
rats with intestinal mucosal damage. The iohexol blood test can therefore be considered a promising 
tool for assessing canine intestinal permeability in veterinary clinical research. Nevertheless, further 
studies using iohexol as intestinal permeability blood marker, particularly in diseased dogs, are 
warranted before firm conclusions can be made on the validity of this test.
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ABBREVIATIONS
51Cr-EDTA  51chromium-labeled ethylenediamine tetra-acetic acid
99mTc-DTPA 99mTc-diethylenetriaminopentaacetate
Å Angstrom
BW Body weight
Da Daltons
DF Dilution factor
DSS Dextran sulfate sodium
EPI Exocrine pancreatic insufficiency
G 3-O-methyl-D-glucose
GI Gastrointestinal
H Hematocrit
HPLC-PAD High-performance liquid chromatography-pulsed amperometric 
detection
HPLC-UV  High-performance liquid chromatography
IBD Inflammatory bowel disease
IQR  Interquartile range
IM Intramuscular
IV Intravenous
IP Intestinal permeability
L  Lactulose
L/R Lactulose-to-rhamnose ratio
MBq  Megabecquerel
MM Molecular mass
mSv  Milli-Sieverts
µCi  Microcurie
Nm Nanometer
PAD Pulsed amperometric detection
PO  Per os
R  Rhamnose
S Sucrose
SC Subcutaneously
SD Standard deviation
SEM Standard error of the median
SIBO Small intestinal bacterial overgrowth
TJs Tight junctions
TBV Total blood volume
TPV Total plasma volume
TSV Total serum volume
TTSV Total test solution volume
TUV Total urine volume
X D-xylose
X/G D-xylose/3-O-methyl-D-glucose ratio
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1. INTRODUCTION
The breakdown of intestinal mucosal integrity is a pathological condition that is 
frequently accompanied by damage to the intercellular tight junctions and ultimately 
leads to increased intestinal permeability. Hyperpermeability is believed to play a key role 
in initiating and developing intestinal and non-intestinal diseases such as inflammatory 
bowel disease, irritable bowel syndrome, type I diabetes, food allergies, and several 
other disorders in humans and animals, including dogs. (Hall, 1999, Farhadi et al., 2003, 
Clayburgh et al., 2004, Teshima and Meddings, 2008, Fasano, 2012a, Suzuki, 2012, 
Teshima et al., 2012)  
In dogs, the common method for assessing the status of intestinal mucosal integrity 
has been histopathological examination of tissue samples that are collected from the 
gut, but this approach is often not the most appropriate or sensitive for various reasons, 
including diagnostic and practical drawbacks. Histopathology as diagnostic tool for 
intestinal permeability may be flawed, because it is known that derangement of the 
canine bowel mucosa often results in increased intestinal permeability while not causing 
histopathological abnormalities, even in individuals with severe clinical symptoms. 
(Hall and Batt, 1990, Bjarnason et al., 1995, Batt, 2000, Willard et al., 2002, Willard 
and Mansell, 2011) In addition, histopathology also requires an invasive approach for 
sampling and collecting tissue samples from the relatively inaccessible canine gut, and 
the use of invasive methods and anesthesia is always required. This invasiveness reduces 
animal welfare and may be especially inappropriate in long-term clinical follow-ups and 
in longitudinal research studies, where serial biopsies are taken in the same individual 
over the study time.
Intestinal permeability testing, on the other hand, has proved to be valuable in the 
diagnosis and follow-up of a variety of clinical diseases and experimental conditions 
for which intestinal mucosal integrity must be evaluated. Intestinal permeability tests 
have shown many advantages, including ease of performance (consists of the oral 
administration of a marker and the subsequent recovery of a sample in urine or blood), 
a low level of invasiveness, and objective assessment of mucosal integrity (i.e. provides 
a numerical index of mucosal pathology, which enables a qualitative and quantitative 
measure of gut damage). Additionally, permeability tests can help in reducing and 
refining the use of dogs in research. This type of testing may be possible to repeat in 
the same dog without significantly jeopardizing its welfare and thereby avoiding the 
need to use additional dogs in the same study, and is also able to replace more invasive 
techniques such as endoscopy or laparotomy, which are needed to collect a tissue biopsy 
for subsequent histopathological analysis. 
However, despite the apparent value of intestinal permeability tests in revealing and 
examining intestinal mucosal damage, these tests are not frequently used by veterinarians 
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or biomedical scientists working with dogs. This is most likely due to a number of flaws 
recognized in the permeability testing methodology, such as relevant downsides of the 
molecules generally used as biomarkers and certain impracticalities of the test.
Permeability testing in dogs was initially performed using chromium 51-labeled 
ethylenediamine tetra-acetic acid (51Cr-EDTA) as a probe. This marker is still considered 
the gold standard molecule for intestinal permeability measurements, but the use of 
and exposure to radioactivity is a considerable limiting factor that has precluded this 
testing option, especially in the clinical setting. To avoid problems associated with 
radioactive labels, intestinal permeability testing using sugar markers such as lactulose 
and rhamnose has been more commonly applied in the more recent years. However, 
measurements using saccharides have been associated with conflicting test results, and 
the use of this testing option in dogs is currently also declining. (Hall, 1999, Suchodolski 
and Steiner, 2003, Batt, 2009, Berghoff, 2011) More recently, iohexol, a radiocontrast 
medium commonly used in medical imaging, has been successfully used as an intestinal 
permeability marker for non-invasive screening of intestinal damage in laboratory 
rats and humans. Iohexol meets the criteria described for permeability markers, but in 
contrast to 51Cr-EDTA and the combination of sugars, this molecule does not involve 
radioactivity, nor is inconsistently degraded by intestinal bacteria. Furthermore, it has 
the added advantages of being inexpensive compared to the other molecules, widely 
available in radiology departments, and of being potentially quantified by different 
analytical techniques. (Stordahl, 1988a, b, Andersen et al., 1992, Halme et al., 1993, 
Andersen and Laerum, 1995, Halme et al., 1997, Halme et al., 2000, Andersen et al., 
2001, Kishimoto et al., 2010)
The main objective of the research described in this thesis was to perform a basic 
comparative study on previously used and potential markers of intestinal permeability 
in dogs. The ultimate goal was to make this testing more easily accessible and reliable 
to clinicians and scientists investigating important canine intestinal and extra-intestinal 
diseases and conditions. 
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2. REVIEW OF THE LITERATURE 
2.1 Intestinal epithelium 
2.1.1 Role of the intestinal epithelial barrier
The luminal surface of the gastrointestinal tract is covered by a single layer of polarized 
and differentiated epithelial cells tightly connected by intercellular junctions. The main 
function of this epithelial layer is to form a dynamic barrier that enables the absorption 
of nutrients, water, ions, vitamins and electrolytes from the external environment into 
the mammalian host. Most of this uptake occurs in the small intestine. Another function 
of the intestinal mucosal barrier is to prevent the uncontrolled entrance of potentially 
damaging compounds such as foreign antigens, carcinogens, pathogens, and toxins 
from the lumen into the submucosa and the blood circulation (Figure 1). (Kararli, 1995, 
Daugherty and Mrsny, 1999, Groschwitz and Hogan, 2009, Catalioto et al., 2011)  
Lumen
Epithelial enterocytes
Submucosa
Nutrients, fluids, electrolytesA)
Pathogens, allergens, toxic productsB)
Uptake
Barrier Lumen
Epithelial enterocytes
SubmucosaBlood system
Blood system
Intercellular
junctions
Figure 1. Schematic diagram of the dual function of the intestinal epithelium: A) uptake of 
beneficial molecules; and B) a barrier against harmful materials. 
2.1.2 Uptake of molecules across the intestinal epithelium
Figure 2 schematically illustrates the uptake of molecules across the intestinal epithelium. 
The passage of luminal substances across the intestinal epithelium essentially takes place 
by absorption or permeation. Absorption is based on the transportation of molecules 
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across the epithelial plasma membrane using an active or facilitated mechanism by 
specific carrier proteins or endocytosis, and this process takes place via a transcellular 
route. Permeation is based on the non-mediated movement of solutes through the 
intestinal epithelium by means of passive diffusion, predominantly following paracellular 
channels but also using smaller transcellular pores. 
The paracellular route is considered the most important means for the permeation of 
small hydrophilic molecules, and its regulation is determined by intercellular junctions 
that bridge the apicolateral border of the epithelial cells. The role of the apical tight 
junctions in the paracellular route is critical in limiting access of harmful substances to 
host tissues and the systemic circulation by reducing the space between adjacent cells 
and the passage of charge entities. (Clayburgh et al., 2004, Groschwitz and Hogan, 2009, 
Ménard et al., 2010, Catalioto et al., 2011, Shen et al., 2011, Fasano, 2012a)
The ability to selectively (rather than absolutely) restrict the non-mediated passive 
diffusion of materials through the paracellular pathway is referred to as intestinal 
permeability. (Travis and Menzies, 1992) This concept mainly refers to the passage of 
ions and small hydrophilic inert molecules of low molecular weight. 
Blood system
By transporters
or endocytosis
Passive diffusion
Paracellular
Absorption
Transcellular
Permeation
Lumen
Epithelial enterocytes
Submucosa
Intercellular
junctions
Figure 2. Uptake of molecules across the intestinal epithelium.
2.2 Measurement of intestinal permeability 
Figure 3 schematically illustrates how intestinal permeability can be measured in 
vivo. Traditionally, measurement of intestinal permeability is performed by orally 
administering specific permeability markers, such as 51Cr-EDTA, or lactulose and 
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rhamnose. The concentration of the recovered markers is then determined, usually in 
urine, after a timed period of 6 to 24 hours, or more rarely in blood after 2 hours. (Hall 
et al., 1989, Bjarnason et al., 1995, Sørensen et al., 1997, Hall, 1999, Suchodolski and 
Steiner, 2003, Arrieta et al., 2006, Batt, 2009, Rodriguez et al., 2009b)
Stomach Small intestine Large intestine
Liver Kidneys Biomarker in urine
Biomarker 
in bloodBlood system
Biomarker
in water solution
Figure 3. Schematic diagram of the principle of gastrointestinal permeability testing. After the oral 
administration of permeability markers, the molecules will cross the epithelium, reach the blood 
system, and then will be eliminated in urine. The markers are quantified in urine after 6 to 24 hours, 
or in blood after 2 hours. Increased permeability is reflected by an increased recovery of the marker.
Under physiological circumstances, the permeability markers pass across the intestinal 
mucosa in a restricted manner. In conditions where the mucosal lining is damaged or 
lost, the passage of permeability probes across the gut barrier occurs freely. (Hall et 
al., 1989, Bjarnason et al., 1995, Bradford et al., 2012) The urinary excretion or blood 
concentrations of the orally-administered markers are influenced by their metabolization 
within the organism and by the glomerular filtration rate. Hence, the biomarkers should 
be completely inert and the test should not be performed in dogs with high serum 
creatinine or urea concentrations. (Hall et al., 1989, Hall, 1999, Suchodolski and Steiner, 
2003, Batt, 2009)
The urine test for intestinal permeability testing in dogs necessitates placement of 
the subject in a metabolism cage to ensure complete urine collection and to prevent 
contamination of the urine with feces containing remains of the non-absorbed biomarker. 
Contamination of urine by feces may occur in the urine-based test, especially in dogs 
with diarrhea, a typical disorder in patients with intestinal mucosal damage. If fecal 
contamination occurs, the results of the testing are considered invalid and the test must 
be cancelled and repeated again after a period of at least 5 days. In dogs, this test method 
was initially performed using a cumulative 24-h urinary excretion of the permeability 
marker. Later, a cumulative 6-hour excretion of the marker was demonstrated to 
be as sensitive as a 24-h collection period. Collecting the urine for 6 hours is more 
advantageous, because a shorter collection period is less stressful for the dog, helps 
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reducing the probability of fecal contamination of urine, and more specifically reflects 
small intestinal permeability. (Hall et al., 1989, Marks and Williams, 1998, Hall, 1999)
A blood-based permeability test using sugars as probes has also been developed for use 
in canine patients. This approach obviates the problems associated with urine collection 
and reduces test time from six to two hours. However, this approach has not gained wide 
popularity due to the analytical constraints of the sugars in plasma samples. (Sørensen et 
al., 1993, Sørensen et al., 1997, Hall, 1999)
2.2.1 Permeability markers
Optimal intestinal permeability probes should have specific desirable physicochemical 
features, including those listed in Table 1. The probe molecules follow first-order 
kinetics of permeation and should be water-soluble, small, non-toxic, non-degradable, 
and not metabolized before, during, or after permeating the intestine. Additionally, they 
should not be naturally present in body fluids. The urinary excretion of probes should be 
complete following intravenous injection, and their quantification should be sensitive, 
accurate, and easy. (Chadwick et al., 1977, Ukabam et al., 1983, Bjarnason et al., 1995, 
Andersen et al., 2001) 
Table 1. Optimal features of intestinal permeability probes. Modified from Andersen et al., 2001.
Transport across intestinal epithelium by permeation
Hydrophilic, lipophobic
Small (specific cross-sectional diameter and molecular weight)
Non-charged 
Non-metabolizable by internal processes
Resistant to intestinal conditions (i.e. non-degradable)
Safe (i.e. non-toxic, innocuous)
Not recognized by the immune system
Artificial (i.e. not present in normal body fluids)
Fully (and rapidly) excreted in urine after intravenous injection 
Accurately and easily quantified 
Inexpensive
Widely available
Various molecules have been used as permeability probes (Table 2), but the majority 
of work in humans, dogs, and experimental animals has employed non-degraded 
radiolabeled chelates (51Cr-EDTA) and small sugar probes expressed as a ratio such 
as disaccharides (lactulose, cellobiose) and monosaccharides (rhamnose, mannitol). 
Although their use is generally not recommended, in the past, polyethylene glycols (PEG 
400) of different molecular masses were also employed (Maxton et al., 1986, Bjarnason 
et al., 1995). More recently, radiocontrast media (iohexol, iodixanol) have additionally 
been successfully utilized as permeability markers in humans and laboratory rats. 
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Table 2. Cross-sectional diameter and weight of selected intestinal permeability markers. 
Class Probe
Molecular size
Å (nm)
Molecular mass
Da (g/mol) References
Radiolabeled chemicals 51Cr-EDTA  10.5 (1.05) 341
Hollander et al., 
1988
Disaccharides
Lactulose  9.5 (0.95) 342
Cellobiose  10.3 (1.03) 342
Monosaccharides
Rhamnose  8.3 (0.83) 164
Mannitol  6.7 (0.67) 182
Contrast media
Iohexol  12 (1.2) 821 Andersen et al., 
2001Iodixanol  15 (1.5) 1550
2.2.2 Routes of intestinal permeation 
In brief, permeation across the intestinal epithelium takes place through the paracellular 
space between adjacent enterocytes and through the cell membranes via a transcellular 
route. The route that a molecule uses for permeation generally depends on its shape, size, 
weight, and charge. It is considered that small hydrophilic solutes permeate across the 
paracellular space, whereas hydrophobic compounds traverse the epithelium mainly via 
a transcellular pathway. (Bjarnason et al., 1995, He et al., 1998, Linnankoski et al., 2010, 
Shen et al., 2011)
The most straightforward hypothesis regarding the routes and rates of permeability 
markers crossing the gut epithelium has been provided by Fihn and co-workers (Fihn 
et al., 2000). Their data suggest that there are three spatially separated aqueous pores of 
different dimensions and density distributed along the crypt–villus axis. The tips of villi 
contain abundant small pores (radius < 6 Å; < 0.6 nm), the bases of the villi have fewer 
intermediate-sized pores (10-15 Å ; 1–1.5 nm), and the crypts have sparse large pores 
(50-60 Å; 5–6 nm) (Figure 4). The aqueous pores at the villous tip are susceptible to 
solvent drag effects (recirculation of water between the crypts and the villus), whereas 
the channels at the base of the villi and in the crypts are not affected. This hypothesis 
is consistent with data from other investigators evidencing that the tight junctions of 
adjacent enterocytes are tighter at the villous tips than in the crypts. Similarly, the 
junctions become progressively tighter from the small to the large intestinal tract. 
(Madara et al., 1980, Maxton et al., 1986, Hollander, 1992, Travis and Menzies, 1992, 
Bjarnason et al., 1995, Rouge et al., 1996, Fihn et al., 2000, Van Itallie et al., 2008, 
Linnankoski et al., 2010, Shen et al., 2011). 
In dogs, the exact size of the intercellular space is unknown, but there is evidence 
suggesting that dogs have a wider extracellular space than humans or rats. (Hall and 
Batt, 1990, He et al., 1998) 
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Villi
Crypts
SMALL (< 9.5 Å)
LARGE (50-60 Å)
MEDIUM (10-20 Å)
Tip
Base
HIGH 
DENSITY
PORE SIZE
PORE NUMBERS
INTERMEDIATE
DENSITY
LOW 
DENSITY
Figure 4. Schematic diagram of the number and size of intercellular pores across the crypt–villus 
axis. 
It has now become accepted that small permeability markers the size of mannitol are 
able to permeate with relative freedom throughout the villus-crypt axis, whereas the 
permeation of larger markers such as 51Cr-EDTA or lactulose occurs at the base of the 
villus and in the crypts, where the tight junctions are leakier and the intercellular channels 
are wider.  (Maxton et al., 1986, Hall et al., 1989, Hall and Batt, 1990, Bjarnason et al., 
1995, Arrieta et al., 2006, Ménard et al., 2010) 
At present, it is also now clearer that paracellular permeability channels are not static 
and they are largely influenced by the regulation of intercellular junctions. The most 
important of these complex intercellular junctions are the apical tight junctions, but 
adherens junctions and desmosomes also play an important role (Figure 5). The apical 
tight junctions are considered the principal determinants of cell–cell proximity and thus 
intestinal permeability. They consist of a complex cluster of numerous transmembrane 
proteins, including claudins, occludin, and junctional adhesion molecule A, being 
connected to the actomyosin ring through zonula occludens proteins. All these structures 
form a network that connects neighboring enterocytes, and are known to be highly 
dynamic. They are regulated in response to numerous extracellular stimuli such as 
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nutrients, cytokines, bacteria or pharmaceuticals, and are closely associated with 
mammalian health and susceptibility to disease. (Hollander, 1992, Travis and Menzies, 
1992, Bjarnason et al., 1995, Hollander, 1999, Clayburgh et al., 2004, Groschwitz and 
Hogan, 2009, Turner, 2009, Ménard et al., 2010, Poritz et al., 2011, Shen et al., 2011, 
Bradford et al., 2012, Fasano, 2012b, a, Suzuki, 2012)
Blood system
Paracellular
route
Tight junction
Desmosome
Adherens junction
Zonula occludens-1
Claudins
Occludin
Actomyosin
Figure 5. Schematic diagram of the paracellular route and intercellular junctions.
2.2.3 Intestinal permeability in disease
The loss of epithelial layer cells as a consequence of apoptosis, or intestinal mucosal 
damage leads to the disruption of epithelial barrier integrity, which is reflected by 
an overall increased intestinal permeability. An elevated permeability secondary to 
mucosal injury is primarily characterized by alterations in the tight junction integrity 
and function, leading to an increased leakiness of the paracellular space. The issue of 
whether hyperpermeability is a cause or consequence of certain disease states is still 
a matter of debate, but currently it is well accepted that a high intestinal permeability 
has pathophysiological significance in the development of various intestinal (e.g. 
inflammatory bowel disease) and systemic (e.g. autoimmune) diseases. This because 
enhanced intestinal permeability can result in mucosal penetration of damaging 
compounds such as antigens, proteases, hydrogen ions, and bacteria and their 
products from the gut lumen to the subepithelial lamina propria. This may elicit a 
variety of pathological processes, such as direct toxicity to the structure and function 
of the mucosa, leading, for example, to a loss of protein from the vessels into the 
intestinal lumen, causing hypoproteinemia. More importantly, it may lead to the 
stimulation of the mucosal immune system and infiltration of inflammatory cells, 
which will amplify and perpetuate the host defense response, leading to chronicity of 
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the gut barrier dysfunction and increasing disease severity. (Bjarnason et al., 1983c, 
Bjarnason et al., 1984, Bjarnason and Peters, 1987, Hollander, 1988, Hall and Batt, 
1990, Teahon et al., 1991, Bjarnason et al., 1995, Hall, 1999, Batt, 2000, Groschwitz 
and Hogan, 2009, Ménard et al., 2010, Catalioto et al., 2011, Bradford et al., 2012, 
Fasano, 2012a)
2.3 Intestinal permeability tests in dogs
Tests of intestinal permeability in dogs have been applied to various clinical research 
conditions and proved to be useful and sensitive in the detection of intestinal mucosal 
damage, in confirming diagnoses, predicting the prognosis of certain enteropathies, 
monitoring the response to treatment of intestinal disease, evaluating the effect of possible 
enterotoxic drugs (e.g. non-steroidal anti-inflammatory drugs), and in quantifying 
inherent differences in intestinal permeation between different species and dog breeds. 
Table 3 provides examples of experimental and clinical conditions in which an altered 
intestinal permeability has been demonstrated in dogs.
Table 3. Experimental and clinical conditions reported to be associated with increased 
gastrointestinal permeability in dogs.
Condition References
Gluten-sensitive enteropathy Hall and Batt, 1990, Hall and Batt, 1991a, 
Hall and Batt, 1991b, Hall and Batt, 1991c, 
Garden et al., 1997, Garden et al., 1998, 
Manners et al., 1994, Garden et al., 1995
Small intestinal bacterial overgrowth Hall and Batt, 1990, Morris et al., 1994, 
Rutgers et al., 1996
Intestinal parasitism (e.g. Giardia spp.) Hall and Batt, 1990
Dietary hypersensitivity and intolerance Rutgers et al., 1995
Inflammatory bowel disease Sørensen et al., 1997, Kobayashi et al., 2007
Species and breed differences Randell et al., 2001
Juvenile and adult age Weber et al., 2002
Small and large body size Weber et al., 2002
Traumatic injury Streeter et al., 2002
Intestinal viruses (e.g. parvovirus) Mohr et al., 2003 
Strenuous exercise Davis et al., 2005
Gut-injury assessment of nonsteroidal anti-
inflammatory drugs (aspirin and meloxicam)
Meddings et al., 1995, Roskar et al., 2011
Intestinal permeability and function testing in dogs has failed to become routinely 
used in small animal practice, and has been inconsistently used for research purposes. 
This is probably due to problems associated with impracticalities in the testing 
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protocols employed, and also because of conflicting test results observed in certain 
studies that could not be explained on the basis of different analytical techniques 
or testing protocols. Although intestinal permeability tests are generally considered 
sensitive in detecting intestinal mucosal damage, permeability measurements have 
not been considered specific for a definitive diagnosis, because permeability may be 
increased in primary intestinal diseases as well as in many non-intestinal disorders. 
(Hall, 1999, Suchodolski and Steiner, 2003, Allenspach et al., 2006, Batt, 2009, 
Berghoff, 2011)
2.3.1 Overview of testing methods
Table 4 presents studies in which intestinal permeability tests have been performed 
in dogs and summarizes the most relevant findings of such studies. Permeability 
testing in dogs was first applied using 51Cr-EDTA as a single probe. This marker is 
still considered the reference molecule for intestinal permeability measurements, 
but exposure to radioactivity is a limiting factor that has considerably affected its 
application. Permeability testing using two different-sized sugar probes such as 
lactulose and rhamnose has become the method most frequently used by clinical 
investigators for assessing small intestinal permeability in dogs. The ratio of two sugars 
does not involve the use of radioactivity, and has been generally thought to provide 
a more reliable permeability index than using 51Cr-EDTA alone. However, findings 
from more recent permeability investigations using saccharides as probe markers have 
provided doubtful test results, and as a consequence, their use in dogs is currently also 
declining. (Hall, 1999, Suchodolski and Steiner, 2003, Allenspach et al., 2006, Batt, 
2009, Berghoff, 2011)
2.3.2 The 51Cr-EDTA test 
51Cr-EDTA is a radiolabeled chelate with a half-life of approximately 28 days that fulfills 
most of the theoretical requirements for an ideal intestinal permeability probe. Intestinal 
permeability testing using this molecule as a single marker has been considered the gold 
standard method for permeability measurements in clinical research studies. 
51Cr-EDTA is water-soluble, metabolically inert (not affected by bacterial activity and 
resistant to intestinal hydrolization), confined to extracellular fluid, completely and 
rapidly excreted by the kidneys, straightforward to assay, extremely stable, relatively 
safe (weak gamma emitter, does not bind to biological materials, lacks chemical toxicity, 
and the estimated radiation dose for the human patient is minimal), and providing care 
is taken in performing this test in dogs, the hazard to personnel is minimal. (Chantler et 
al., 1969, Lökken, 1970, Ahrens and Aronson, 1971, Bjarnason et al., 1983a, Bjarnason 
et al., 1983b, c, Elia et al., 1987, Hall et al., 1989, Katz and Hollander, 1989, Hall and 
Batt, 1990, Lifschitz and Shulman, 1990, Bjarnason et al., 1995)  
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Table 4. Intestinal permeability tests used in dogs. 
Method Study Most relevant findings
51Cr-EDTA Hall et al., 1989 ·	 Test validation on a heterogeneous group of clinically healthy adult dogs.
Hall and Batt, 1990 ·	 Increased permeability associated with small intestinal disease (gluten-sensitive enteropathy, giardiasis 
and SIBO) in a heterogeneous group of dogs.
Hall and Batt, 1991a ·	 Primary permeability defect in the pathogenesis of gluten-sensitive enteropathy in Irish Setters.
Batt et al., 1992 ·	 Enhanced permeability as a consequence of SIBO in apparently healthy Beagles.
Marks and Williams, 1998 ·	 Six-hour urinary recovery as an alternative to 24-h recovery.
Vaden et al., 2000 ·	 Permeability was not increased in six Soft-Coated Wheaten Terriers of both sexes with familial protein-
losing enteropathy, protein-losing nephropathy, or both, when test results were compared with four 
random-source male dogs used as controls.
Cellobiose
and mannitol
Hall and Batt, 1991c ·	 Use on Irish Setters with gluten-sensitive enteropathy.
Vaden et al., 2000 ·	 Permeability was not increased in six Soft -Coated Wheaten Terriers of both sexes with familial protein-
losing enteropathy, protein-losing nephropathy, or both, when test results were compared with four 
random-source male dogs used as controls.
Lactulose
and rhamnose
Rutgers et al., 1992 ·	 Use on dogs with diet-sensitive intestinal disease.
Elwood et al., 1993 ·	 A multiple sugar combination for intestinal permeability and function testing in dogs.
Quigg et al., 1993 ·	 Increased permeability in heterogeneous group of dogs with gastrointestinal disease with 
panhypoproteinemia. 
·	 No significant differences between a heterogeneous group of healthy dogs and a heterogeneous group of 
dogs with gastrointestinal disease.  
Sørensen et al., 1993 ·	 Development of high performance liquid chromatography with pulsed amperometric detection (HPLC-
PAD) for the quantification of lactulose, rhamnose, 3-O-methyl-D-glucose, and xylose in the urine of a 
heterogeneous group of healthy dogs. 
Morris et al., 1994 ·	 Increased permeability in laboratory Beagles with repeated episodes of diarrhea associated with SIBO 
after experimental renal surgery and dietary change.
Rutgers et al., 1995 ·	 Abnormal permeability in dogs with dietary hypersensitivity and intolerance. 
·	 Successful treatment was matched with significant reductions in permeability.  
Rutgers et al., 1996 ·	 Increased permeability in a heterogeneous group of dogs with chronic intestinal disease and SIBO.
Sørensen et al., 1997 ·	 Development of HPLC-PAD for the quantification of lactulose, rhamnose, 3-O-methyl-D-glucose, and 
xylose in the plasma of a heterogeneous group of healthy dogs, dogs with IBD, and dogs with SIBO.
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Method Study Most relevant findings
Lactulose
and rhamnose
Garden et al., 1997 ·	 Reference range and repeatability for urine test in healthy adult Irish Setters. 
·	 No significant differences in permeability according to sex or age in adults.
Garden et al., 1998 ·	 Intrinsic differences were shown in permeability between Irish setters and a heterogeneous group of 
control dogs of other breeds maintained in similar environmental conditions. 
·	 Both urine and blood tests were used, but rhamnose recovery did not correlate between the two methods.
Steiner et al., 2000 ·	 Development of anion-exchange HPLC-PAD for the quantification of sucrose, lactulose, rhamnose, 
3-O-methyl-D-glucose, and xylose in the urine of dogs. 
Randell et al., 2001 ·	 Permeability differs between healthy dogs of different breeds, and between dogs and cats.
Steiner et al., 2002 ·	 Kinetic study of sucrose, lactulose, rhamnose, 3-O-methyl-D-glucose, and xylose in healthy male Beagles, 
showing that a 6-h urine collection period is sufficient for gastrointestinal permeability testing.
Streeter et al., 2002 ·	 Permeability is altered in dogs with traumatic injury.
Weber et al., 2002 ·	 Puppies (12 weeks old) have higher permeability than adults (60 weeks old).
·	 Large-sized dogs had higher permeability than small dogs.
Mohr et al., 2003 ·	 Increased permeability in dogs with acute parvoviral infection.
Davis et al., 2005 ·	 Increased permeability in racing Alaskan sled dogs after sustained strenuous exercise, which returned to 
normal within 2 weeks of normal activity.
Royer et al., 2005 ·	 Increased permeability in stressed racing Alaskan dogs with gastric ulcers.
Allenspach et al., 2006 ·	 No significant differences in permeability in a heterogeneous group of dogs with chronic enteropathies 
before and after treatment. 
·	 Permeability tests did not correlate with histological findings. 
Kobayashi et al., 2007 ·	 Increased permeability in a heterogeneous group of dogs with lymphocytic-plasmacytic enteritis compared 
to healthy control dogs. 
·	 Permeability tests correlated with histological findings. 
Craven et al., 2007 ·	 Absence of increased permeability in a heterogeneous group of client-owned dogs before, during, and 
after receiving meloxicam or carprofen. 
Rodríguez et al., 2009 ·	 Kinetic study of sucrose, lactulose, rhamnose, 3-O-methyl-D-glucose, and xylose in dog serum after 
orogastric administration.
Rodriguez et al., 2009b ·	 Development of gas chromatography-mass spectrometry for the quantification of sucrose, lactulose, 
rhamnose, 3-O-methyl-D-glucose, and xylose in canine serum.
Lactulose
and mannitol
 Roskar et al., 2011 ·	 Increased gastrointestinal permeability in Beagles during and after receiving meloxicam was demonstrated 
using a plasma-based test.
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The 51Cr-EDTA test was validated as a urine-based test for canine use in 1989 (Hall et 
al., 1989), and has subsequently proved valuable in the detection of mucosal damage in 
dogs affected with gluten-sensitive enteropathy, small intestinal bacterial overgrowth, and 
giardiasis (Hall and Batt, 1990). The urine test needs the placement of the subject in a 
metabolism cage for 6 to 24 hours to ensure complete urine collection, and to prevent fecal 
contamination of the urine. Clinically healthy dogs excreted less than 17% of the orally 
administered dose of 51Cr-EDTA in a 24-h urinary recovery test (Hall et al., 1989), whereas 
less than 12% was excreted in a 6-h urinary recovery test (Marks and Williams, 1998). 
The 51Cr-EDTA test is typically carried out by using a single marker only. This has been 
thought to affect the test’s sensitivity, as non-mucosal factors such as renal function, intra-
luminal dilution and intestinal transit time could all affect, at least in theory, the urinary 
recovery of the orally administered probe. Nevertheless, the optimal physicochemical 
characteristics of 51Cr-EDTA are believed to compensate this inconvenience when using it 
in permeability studies. (Bjarnason et al., 1995, Hall, 1999) However, the main drawbacks 
of using 51Cr-EDTA and the main cause of its current unpopularity are associated with 
the costs of the radioisotope and the equipment required, and the technical constraints, 
including safety concerns in using a radioactive material. 51Cr-EDTA is considered a 
relatively safe radionuclide for diagnostics in nuclear medicine for both the patient and 
the operator, as the radiation dose delivered to a patient after the oral administration of 
3.7 MBq (100 µCi) of 51Cr-EDTA is calculated to be less than 0.163 mSv (a dose that is 
far lower than any other nuclear diagnostic procedure and even six-fold lower than the 
radiation emitted during a routine abdominal radiograph). Moreover, the risk to operators 
handling the radioactive nuclide or administering the test solution containing 51Cr-EDTA 
is considered negligible, providing that care is taken to avoid external contamination from 
vomit or urine spills from the canine patient. However, the use of radioisotopes requires 
expensive materials and equipment, and is restricted to legally-licensed operators and 
facilities. (ICRP, 1998, Hall, 1999, ICRP, 2002, ICRP, 2002) 
Nevertheless, among all the positive and negative features of 51Cr-EDTA, the physiological 
and biochemical inertness of this molecule that makes it resistant against bacterial 
degradation, and the ease with which it can be quantified in urine using a γ-counter, makes 
it an especially valuable marker for intestinal permeability studies in comparison with 
sugars. Of paramount importance is the absolute resistance against bacterial degradation, 
because intestinal permeability testing is principally aimed at individuals who may 
potentially suffer from dysbiosis, including small intestinal bacterial overgrowth (SIBO), 
a condition that may be precipitated in patients with intestinal abnormalities and that 
may also be present in dogs as a subclinical entity in certain breeds such as Beagles. 
(Batt et al., 1992, Hall and Batt, 1996, Marks and Williams, 1998, Hall, 1999)
2.3.3 The dual sugar test 
The simultaneous administration of two sugar molecules differing in size and weight, 
and the subsequent assessment of their differential urinary or blood recovery has been 
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more commonly used for permeability testing than the 51Cr-EDTA test.  Results from the 
use of two markers for permeability testing are generally believed to be more sensitive 
than using a single probe, because the two molecules should be equally influenced by 
non-mucosal factors and the sources of error are considered to affect both probes equally. 
(Menzies, 1974, 1984, Bjarnason et al., 1988, Bjarnason and Peters, 1989, Hall and Batt, 
1991c, Bjarnason et al., 1995, Hall, 1999)  
In dogs, the differential permeability sugar test has typically been performed by 
combining a disaccharide such as lactulose (or cellobiose) and a monosaccharide 
such as rhamnose (or mannitol). The disaccharides lactulose and cellobiose are both 
rapidly metabolized by colonic bacteria, and their absorption theoretically reflects small 
intestinal permeability. The permeation of the monosaccharides rhamnose and mannitol 
is believed to occur throughout the crypt–villus axis in the small intestine, and their 
uptake reflects small intestinal permeability. An overall increased intestinal permeability 
is reflected by an increased disaccharide/monosaccharide ratio, which is explained by 
an increased recovery in the urine or blood of the larger molecule (i.e. disaccharide) 
coupled with a decreased recovery of the smaller one (i.e. monosaccharide). (Menzies, 
1984, Hall and Batt, 1991c, Bjarnason et al., 1995, Hall, 1999, Arrieta et al., 2006)
The dual intestinal permeability test is frequently combined with sucrose, xylose, and 
3-O-methyl-D-glucose. Sucrose, a monosaccharide that is immediately digested by 
the jejunal mucosa, has been used for the concurrent measurement of gastroduodenal 
permeability. Xylose and 3-O-methyl-D-glucose are monosaccharides that have been 
used for the measurement of small intestinal absorptive function. The simultaneous 
measurement of gastric permeability and the absorptive capacity of the small intestine 
usually provides complementary information on the gastrointestinal tract, which can be 
useful for estimation of the overall severity of mucosal damage. (Menzies, 1974, Elwood 
et al., 1993, Bjarnason et al., 1995, Meddings et al., 1995, Rutgers et al., 1995, Rutgers 
et al., 1996, Hall, 1999, Suchodolski and Steiner, 2003, Batt, 2009) 
The canine differential sugar test was first described as a urine test using cellobiose and 
mannitol as permeability markers (Hall and Batt, 1991c), but the lactulose and rhamnose 
test has become the standard sugar intestinal permeability test in dogs. Although the 
analytical procedure is technically more demanding for lactulose and rhamnose than for 
cellobiose and mannitol, the use of the latter combination has been discouraged because 
there is some sugar hydrolysis caused by small intestinal cellobiose activity of brush-border 
enzymes, and also because endogenous mannitol has been detected in dogs and in the urine 
of fasted subjects. (Dahlqvist, 1962, Laker et al., 1982, Noone et al., 1986, Hall and Batt, 
1991c, Elwood et al., 1993, Quigg et al., 1993, Bjarnason et al., 1995, Hall and Batt, 1996) 
The lactulose/rhamnose test, and more recently the lactulose/mannitol assay, has been 
adapted for blood methods in dogs. The blood approach is more practical than the 
urine-based test during the testing procedure in dogs, since collecting a blood sample 
between 90 and 180 minutes after dosing (Sørensen et al., 1997, Rodríguez et al., 2009) 
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is more advantageous than the cumulative recovery of urine over a period of at least 5 
hours and sometimes up to 24 hours. However, protocols utilizing permeability markers 
recovered in urine have been more commonly used than blood methods, mainly because 
the quantification of sugars in serum or plasma is more laborious and time consuming 
than in urine. Although the determination of saccharides in the urine and blood of dogs 
has been improved and has made testing simpler than previous methodologies used in 
the past, the detection of sugars in blood is more cumbersome than in urine, essentially 
because the blood sample must be deproteinized and the endogenous glucose must be 
oxidized. (Sørensen et al., 1993, Sørensen et al., 1997, Hall, 1999, Steiner et al., 2000, 
Rodriguez et al., 2009a, Rodriguez et al., 2009b)
The measurement of di- and monosaccharides used in permeability screening is performed 
by high-performance liquid chromatography. More recently, a gas chromatography–mass 
spectrometry (GC-MS) method for the quantification of lactulose, rhamnose, xylose, 
3-O-methylglucose, and sucrose in canine serum has been developed and analytically 
validated. This method was shown to be accurate, precise, and reproducible for the 
simultaneous measurement of sugar probes in canine serum. (Rodriguez et al., 2009b, 
Rodríguez et al., 2009)
The use of saccharides for assessing intestinal permeability has been associated 
with inconsistent results (Allenspach et al., 2006, Kobayashi et al., 2007), and such 
inaccuracies have been ascribed to some of the physicochemical properties of the 
saccharides. Although widely claimed as inert molecules, sugars are subject to intestinal 
hydrolization and bacterial degradation, phenomena that can considerably affect the 
recovery of the markers, especially in patients with bacterial overgrowth or dysbiosis. 
(Elia et al., 1987, Katz and Hollander, 1989) This circumstance has largely been 
overlooked because non-mucosal factors such as bacterial metabolism of probes would 
not affect test results, as these are expressed as the ratio of two molecules. However, 
it is well known that the rate of bacterial metabolism for each of the two sugars is not 
necessarily identical, so the ratio of two molecules may not necessarily provide accurate 
permeability test results. (Laker et al., 1982, Noone et al., 1986, Quigg et al., 1993, 
Riordan et al., 1997, Garden et al., 1998) Similarly, it is known that the urinary excretion 
of the saccharides used as permeability probes has been unequal and incomplete 24 
hours after intravenous administration in clinically healthy dogs (e.g. rhamnose 72%) 
(Hall and Batt, 1996, Garden et al., 1998), phenomena that could also lead to errors in 
the data generated from intestinal permeability tests using such sugars. 
In humans, it has been reported, however, that the sensitivity of the two-sugar test is low 
and inadequate in patients that have SIBO with an overgrowth primarily composed of 
colonic-type bacteria. (Riordan et al., 1997) In dogs, different rates of sugar metabolism 
may lead to variations in the lactulose/rhamnose ratios, a process that may be further 
aggravated in subjects with SIBO. (Hall and Batt, 1996, Hall, 1999)  
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The lactulose/rhamnose intestinal permeability test in blood for dogs has been developed 
(Sørensen et al., 1993, Sørensen et al., 1997, Rodriguez et al., 2009b), but because the 
analysis of sugars in plasma or serum is technically demanding, this blood approach has 
not gained widespread use in veterinary medicine. 
2.3.4 Contrast media for permeability testing
Non-ionic water-soluble iodinated radiographic contrast media of low- and iso-osmolar 
types, such as iohexol and iodixanol, are widely used in human and small animal 
medicine for X-ray-based imaging techniques such as radiography and computed 
tomography (Wood et al., 1985, Kishimoto et al., 2010), and for assessing the glomerular 
filtration rate (Moe and Heiene, 1995, Gleadhill and Michell, 1996). These agents have 
also recently been identified as valuable molecules for measuring intestinal mucosal 
damage in humans and rats.
Iohexol and iodixanol agents were selected because they share many physicochemical 
features required for permeability probes, including an appropriate molecular size and mass, 
hydrophilicity, intestinal uptake by passive diffusion, non-reactivity, non-toxicity, metabolic 
stability, and easy quantification after urine excretion. (Andersen and Laerum, 1995)
In particular, the 24-h excretion rates of iohexol in urine after IV application have been 
reported to be 99% for humans, 96.1 ± 4.7% for dogs (98 ± 4% after 7 days), and 91.5 
± 3.6% for rats (93–95% after 7 days). In addition, the urine specimens in these species 
did not reveal any metabolized forms of iohexol, so it has been concluded that iohexol is 
excreted unchanged in the urine of these species after intravenous application. Moreover, 
iohexol is a substance that may be detected in canine plasma after oral administration to 
dogs. As a radiocontrast agent, it is frequently available in the departments of veterinary 
radiology, and it has been successfully used as a preclinical marker of intestinal damage 
in experimental rats, and clinically in human patients. (Aakhus et al., 1980, Mützel and 
Speck, 1980, Stordahl, 1989a, Solheim et al., 1991, Andersen et al., 1992, Halme, 1992, 
Halme et al., 1993, Agut et al., 1995, Gaspari et al., 1995, Halme et al., 1997, Halme et 
al., 2000, Andersen et al., 2001, Finco et al., 2001, Gerova et al., 2011)
In contrast to the above-described intestinal permeability markers used in dogs, iohexol 
is non-radioactive, is not inconsistently degraded by intestinal bacteria, and has more 
potential applications as it may be simultaneously used, for example, in the radiographic 
examination of intestinal morphology by X-ray fluorescence and possibly also computed 
tomography densitometry. (Grönberg et al., 1983, Stordahl, 1989b, Lundqvist et al., 
1995, Rencken et al., 1997)  
26 Aims of the Study 
3. AIMS OF THE STUDY
The main objective of this work was to improve fundamental aspects of intestinal 
permeability testing in dogs in order to make the screening of intestinal mucosal damage 
A) more practical and accurate, and B) more attractive and accessible for the non-
invasive investigation of canine intestinal and extra-intestinal diseases in veterinary 
clinical and biomedical research. Preclinical studies using laboratory Beagle dogs or 
Sprague-Dawley rats were performed, and the specific aims of these studies were: 
1. To evaluate and compare the most relevant markers used in intestinal permeability 
testing in dogs. Specifically, the gold standard probe 51Cr-EDTA and the most 
commonly used probes lactulose and rhamnose were simultaneously used in 
healthy laboratory Beagles, in order to elucidate whether the use of 51Cr-EDTA and 
such sugars are truly comparable for the measurement of intestinal permeability in 
dogs.
2. To determine the relevance of using a single marker such as 51Cr-EDTA or 
lactulose, or a combination of two as a ratio, such as 51Cr-EDTA/rhamnose or 
lactulose/rhamnose, for the measurement of intestinal permeability in dogs. 
3. To determine the reliability of intestinal permeability blood tests in dogs in 
comparison with the urine-based test.
4. To compare iohexol and the gold standard marker 51Cr-EDTA for the assessment 
of intestinal permeability in healthy laboratory Beagle dogs.
5. To pre-clinically evaluate iohexol as an intestinal permeability marker in diseased 
subjects using a well-characterized laboratory murine model of intestinal disease.
 Materials and Methods 27
4. MATERIALS AND METHODS 
4.1 Experimental animals
A total of 33 laboratory Beagle dogs and 30 Sprague-Dawley rats were used in the 
studies (Table 5). 
Table 5. Characteristics of the animals used in the studies. 
Species 
and breed/strain Study
Number 
(and sex) Age Weight Clinical status
Beagle dogs I 19 (♂) 11–40 mo. 
(mean 18)
12.4–17 kg 
(mean 14.9)
Healthy, no 
gastrointestinal (GI) 
signs.
II 31 (29♂, 2♀) 1–5 yrs.
(mean 1.9)
10.3–17.8 kg
(mean 15.1)
Healthy, no GI 
signs.
III 13♂ 17–46 mo.
(mean 23.1)
13–17 kg
(mean 15)
Healthy, no GI 
signs.
IV 7 (5♂, 2♀) 3–7 yrs.
(mean 5.4)
10.4–19.5 kg
(mean 14)
Healthy, no GI 
signs.
Hsd:Sprague 
Dawley®™SD®™ 
rats
V 30 (28♀)
Two were 
excluded 
because of 
esophageal 
reflux.
12–13 wks. 200–250 g Specific pathogen 
free, healthy, no GI 
signs.
à All developed 
GI signs after DSS 
exposure.
The experimental protocols using dogs (Studies I, II, III, IV) were approved by the local 
Ethics Committee for Animal Experiments of the University of Helsinki, Finland. The 
project using rats (Study V) was approved by the local Ethics Committee for Animal 
Experiments of the University of Turku, Finland.
All the dogs and rats were cared for and used in experiments in accordance with the principles 
outlined in the prevailing Finnish and European legislation on the use of vertebrate animals 
for scientific purposes (European Community Council Directive 86/609/EEC, Council of 
Europe, 1986; Finnish Government, 1985; Finnish Government, 1996).
4.1.1 Dogs 
All the Beagles used in the studies were purebred laboratory dogs that were supplied by 
approved laboratory animal breeders (Harlan-Winkelmann GmbH, Borchen, Germany; 
and the National Laboratory Animal Center, University of Kuopio, Finland). All the 
dogs were acclimatized for at least one month prior to the start of the experiments, and 
they were housed in the former experimental dog facilities of the Faculty of Veterinary 
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Medicine, University of Helsinki, Finland. The dogs were maintained in indoor pens, 
spending about four hours daily in outdoor runs, and were exposed to both natural 
and artificial light (from 07:00 to 16:00). The environmental temperature indoors was 
maintained within a range of approximately 15–24 ºC. Feeding throughout the studies 
consisted of 1.5 cans/dog of a commercial canned dog food (Pedigree®, Fortivil 400 g, 
Waltham®, Masterfoods Ltd, Helsinki, Finland), which was given twice daily. Water 
was freely available at all times.
None of the dogs were considered obese based on visual observations, and all the dogs 
were determined to be healthy based on results from physical examinations, and after 
interpretation of hematological and serum biochemical analysis. Blood urea nitrogen and 
serum creatinine concentrations suggested normal renal function in all dogs. Exocrine 
pancreatic function was considered normal based on measurements of serum trypsin-like 
immunoreactivity concentrations (Williams and Batt, 1988). Serum folate and cobalamin 
concentrations suggested normal carrier-mediated absorption in the proximal and distal 
small intestine (Batt and Morgan, 1982). 
A few days prior to commencing the intestinal permeability testing, the dogs were 
dewormed with fenbendazole (Axilur®, Intervet International, Boxmeer, The Netherlands) 
at a dose of 50 mg/kg PO for 3 consecutive days. Subsequent examination of fecal 
samples for endoparasitic ova was negative for all dogs.
4.1.2 Rats 
All the Hsd:Sprague Dawley®™SD®™ (SD) rats used in study V were obtained from 
a breeding colony supplied by a semi-barrier facility of the Central Animal Laboratory, 
University of Turku, Finland. 
Prior to the commencement of the study, the rats enrolled in the study were acclimatized 
for 21 days and were determined to be healthy on the basis of individual physical 
examinations, and specific pathogen-free based on the results of routine microbiological 
screening performed on the rat colony in accordance with European recommendations. 
(Nicklas et al., 2002)
At the commencement of the study, the rats were 12 weeks old and ranged in body 
weight from 200 to 250 g. The rodents were housed in groups of six and were maintained 
in opened stainless steel cages (59.5 x 38.0 x 20.0 cm) with solid bottoms and Aspen 
chips used as bedding (Tapvei Ltd, Kaavi, Finland). An Iglo and some nesting material 
were used as enrichment. Cage change was undertaken twice a week. The environment 
in the room was maintained at an approximate temperature of 22 °C (range 20 to 23 °C), 
a relative humidity of 50 to 60%, and artificial illumination with a 12-h light/dark cycle 
(lights on at 06:00 am). Throughout the study period, all the rats were fed a standard rat 
chow (SDS, Special Diet Services, Whitham, Essex, UK) ad libitum, and tap water was 
provided without restrictions in polycarbonate bottles. 
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Gastrointestinal damage was induced by a 7-day administration of 5% dextran sulfate 
sodium (DSS) in drinking water, which has been shown to produce symptoms in 
laboratory rats comparable to inflammatory bowel disease (IBD) observed in humans. 
After exposure to DSS, the rats developed the typical clinical symptomatology associated 
with inflammatory bowel disease, and all the subjects were determined to be affected 
based on physical examination and evidence of changes in fecal consistency, diarrhea 
and hematochezia. (Gaudio et al., 1999, Chen et al., 2007) 
To assess the possible toxic effects of DSS on kidney function, creatinine concentrations 
were determined in urine samples using a Konelab 30i automatic analyzer (Thermo 
Scientific, Waltham, MA, USA). The iohexol-to-creatinine ratio was also calculated 
similarly to the urinary protein-to-creatinine ratio for the assessment of proteinuria in 
dogs. (White et al., 1984, Grauer et al., 1985) The results from the serum creatinine 
concentrations suggested normal renal function before and after exposure to DSS.
4.2 Permeability testing in dogs 
Before intestinal permeability testing was carried out in dogs (I, II, III, IV), their food was 
withheld the night before and throughout the study, but water was freely available at all 
times. Following the overnight fasting period and immediately prior the administration 
of the permeability markers delivered in the test solutions, the body weights of the dogs 
were measured and a baseline blood sample was collected from each subject.
On the same morning of the experiments, fresh individual test solutions were made by 
dissolving the probe molecules with distilled water. All the dogs received the test solutions 
intragastrically by using an orogastric tube. If esophageal reflux or fecal contamination 
of urine was observed, the test was cancelled and repeated after an interval of at least 
five days (Hall et al., 1989). 
In studies using 51Cr-EDTA as permeability probe (I–IV), individual test solutions 
consisted of approximately 3.7 MBq (100 µCi) of the radioisotope (Nycomed Amersham 
plc, Little Chalfont, Buckinghamshire, United Kingdom) dissolved in 50 ml of distilled 
water. A counting standard from the test solution was retained in a 1-ml aliquot, which 
was further diluted (1:50) before radioactivity measurements. 
In study I, two test solutions were administered. The solution containing 51Cr-EDTA was 
administered first, and then immediately followed by the administration of 200 mL of 
distilled water containing a mixture of 2 g lactulose (L), 2 g rhamnose (R), 2 g D-xylose 
(X), 1 g 3-O-methyl-D-glucose (G), and 8 g sucrose (S). 
In study II, the 51Cr-EDTA test was simultaneously performed on urine and serum in the 
same dogs (n = 31). The testing was performed a total of 43 times, once in 25 dogs and 
thrice in 6 dogs. 
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In study III, the 51Cr-EDTA permeability test in blood was simultaneously performed on 
serum and plasma. Two concurrent blood samples were withdrawn from the cephalic 
veins of each dog at 3 and 5 h post-administration of the test solution. In this study, one 
of the blood samples was transferred to clotting factor activator tubes to obtain serum, 
and the other one was transferred to heparinized tubes to obtain plasma. All the blood 
samples were centrifuged for 12 min at 2100 g to obtain either serum or plasma. The sera 
and plasma were separated into 1- to 2-ml aliquots for the measurement of radioactivity. 
In study IV, a single dose of 10 mL of Omnipaque 300 (Amersham Health) containing 
6471 mg of iohexol was added to a test solution containing 51Cr-EDTA dissolved in 50 
mL of distilled water.
In studies I and II, all of the dogs were sedated with medetomidine (Domitor®, Orion 
Pharma Ltd, Turku, Finland), 25 µg/kg IM,  just prior to the administration of the 
test solution and to facilitate the emptying of the urinary bladders via catheterization. 
During the mild sedative state of the dogs, they received the test solutions by orogastric 
gavage, and subsequently after that atipamezole (Antisedan®, Orion Pharma Ltd, Turku, 
Finland), 100 µg/kg IM, was injected to reverse the sedative effects of medetomidine. 
The dogs were then placed in metabolic cages for 6 hours for urine collection, and at 
the end of this period medetomidine at 25 µg/kg was once again injected IM to each 
dog prior to catheterization of the urinary bladders for urine collection. All the urine 
collected from the urinary bladders and from the metabolic cages was pooled, and the 
total urine volume was determined and recorded for later test calculations for each dog. 
In studies III and IV, no sedative drugs were used.
In studies I and II, a 2-ml urine aliquot from the total urine volume was retained for the 
measurement of 51Cr-EDTA radioactivity. In study I, a further 2-ml tube was retained 
for analysis of sugars, which was first stored at -20 ºC and subsequently shipped on dry 
ice to the GI Laboratory, Texas A&M University, College Station, Texas, USA, for the 
analytical procedure.
In studies II and IV, all timed blood samples were withdrawn from cephalic veins post-
administration of the test solution (study II at 2, 3, 4, 5, and 6 hours; study IV at 0.5, 1, 
2, 3, 4, 5, and 6 hours). 
4.3 Permeability testing in rats 
One mL of Omnipaque 300® (iohexol, 647.1 mg/mL) was dosed intragastrically 
to each rat using a feeding needle. No sedative drug was used before, during or after 
administration. The animals were placed in individual metabolic cages for urine collection 
during 24 hours. After all urine had been recovered, the volumes were recorded and the 
samples frozen at -18 ºC until later analysis. If esophageal reflux of iohexol or fecal 
contamination of urine was observed, the test was cancelled.
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4.4 Measurement of permeability markers  
All the control, urine, serum, and plasma aliquots were measured for 51Cr-EDTA gamma 
ray emissions by use of a counter (LKB-Wallac 1270 Rackgamma II gamma counter, 
LKB-Wallac, Turku, Finland). Gamma ray emissions in the aliquots were counted for 
10 min, and all the quantifications were performed during the same evening of the 
experiments and within 12 hours of the end of the collection period for each animal at 
the former facilities of the Central Laboratory of the Department of Clinical Veterinary 
Sciences, University of Helsinki, Finland.
The analysis of sugars in canine urine (study I) was performed by high-performance 
liquid chromatography in accordance with a previously reported methodology (Steiner 
et al., 2000).
The iohexol concentration in the urine of rats (study V) and serum of dogs (study IV) 
was analyzed by high-performance liquid chromatography with ultraviolet detection 
[(HPLC)-UV] after solid phase extraction, as previously described elsewhere. (Klenner 
et al., 2007, Pöytäkangas et al., 2010)
4.5 Formulas to calculate the recovery rates of 51Cr-EDTA and iohexol.  
The amount of 51Cr-EDTA in urine, serum, and plasma (I–IV) was calculated as a 
percentage of the orally-ingested test solution using the formulas in Table 6. 
The amount of iohexol in rat urine and dog serum as a percentage of the orally-ingested 
test dose was calculated using the formulas in Table 7. 
Table 6. Formulas to calculate the amount of 51Cr-EDTA as a percentage of the orally-ingested 
test solution in canine urine, serum, and plasma. The total blood (TBV), serum (TSV), and plasma 
(TPV) volumes were estimated according to formulas published elsewhere. (Woodward et al., 
1968, Jain, 1986). Modified from studies II and III.
51Cr-EDTA in urine (%) = cpm in urine aliquot (1 mL) x TUV (mL) x 100
cpm in standard aliquot (1 mL) x 50 (DF) x TTSV (mL)
51Cr-EDTA in serum (%) = cpm in serum aliquot (1 mL) x TSV (mL) x 100
cpm in standard aliquot (1 mL) x 50 (DF) x TTSV (mL)
51Cr-EDTA in plasma (%) = cpm in serum aliquot (1 mL) x TPV (mL) x 100
cpm in standard aliquot (1 mL) x 50 (DF) x TTSV (mL)
TBV (mL) = BW (kg) x 100 (mL/kg)
TSV and TPV = TBV (mL) x (100 – H)
100
Legend: cpm, counts per minute; TUV, total urine volume; TBV, total blood volume; TSV, total 
serum volume; TPV, total plasma volume; TTSV, total test solution volume; TPV, total plasma 
volume; DF, dilution factor; BW, body weight; H, hematocrit
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Table 7. Formulas to calculate the amount of iohexol as a percentage of the orally-ingested test 
solution in rat urine and dog serum. Modified from studies IV and V.
Iohexol in rat urine (%) = µg/mL in urine x TUV (mL) x 100
µg in test solution (1 mL Omnipaque 300)
Iohexol in dog serum (%) = µg/mL in serum x TSV (mL) x 100
µg in test solution (10 mL Omnipaque 300)
Legend: TUV, total urine volume; TSV, total serum volume.
4.6 Statistical analysis (I–V)
The following statistical analyses were used in the original articles.
I. The Shapiro-Wilk test was used to assess the normality of the distribution of 
each variable. Normally distributed variables were expressed as means (± SD, 
range), and other variables as medians (range). Pearson’s correlation coefficient 
was used to measure the associations between pairs of probe markers that both 
followed a normal distribution, whereas Spearman’s rank correlation coefficients 
were calculated if one of the variables was not normally distributed. Values of 
P less than 0.05 were considered significant. Statistical analysis was performed 
using a commercial software program (SAS system for Windows, release 9.2, 
SAS Institute, Cary, NC, USA). 
II. Results were expressed as mean ± SD.  Coefficients of variation are presented as 
percentages (CV %). The relationship between the results in urine and blood was 
determined using the Pearson correlation coefficient (r), which was calculated 
using statistical analysis tools from a software program (Microsoft® Excel 2002, 
©Microsoft Corporation 1985-2001).
III. Statistical analysis was performed using SPSS 11.0 software (SPSS Inc, Chicago, 
IL, USA). The data distribution was analyzed by applying the Kolmogorov–
Smirnov test and was determined to be Gaussian. Due to the normal distribution, 
results were expressed as the mean and standard deviation (mean ± SD). The 
significance of the difference in test results between serum and plasma samples was 
determined by one-way analysis of variance, and where appropriate, the Student–
Newman–Keuls test was used for the comparison of means. The relationship 
between the results was determined using the Pearson correlation coefficient (R). 
A P-value of less than 0.05 was regarded as statistically significant. The Bland–
Altman test was used to analyze the difference and potential bias between the two 
methods. The repeatability coefficient was calculated as 1.96 times the SD of the 
differences.
IV.  The MedCalc software program (v. 11.2.1.0) was used for statistical analysis. 
According to the Shapiro-Wilk test, serum concentrations of 51Cr-EDTA and 
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iohexol followed a normal distribution. Longitudinal variables were considered 
independent, and the data were processed using a simple linear regression model, 
correlation analysis and paired-samples t-test. P < 0.05 was considered significant.
V. Statistical analysis was performed using SPSS 11.0 software (SPSS Inc, Chicago, 
IL, USA). The data were analyzed with the Wilcoxon signed-ranks test, and were 
expressed as the median (IQR). 
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5. RESULTS 
5.1 Urinary measurements and statistical comparisons of the markers 
after their concurrent oral administration to healthy adult male 
Beagles (I)
The individual age and weight of the nineteen healthy male laboratory Beagles used in 
study I, and the percentage urinary recovery of the 6 markers used in this study to assess 
gastrointestinal permeability and absorptive function after their simultaneous orogastric 
administration are presented in Table 8.
The urinary excretion of 51Cr-EDTA (P = 0.155), lactulose (P = 0.331), rhamnose (P = 
0.388), the ratio of 51Cr-EDTA/rhamnose (P = 0.077), lactulose/rhamnose (P = 0.062), 
3-O-methyl-D-glucose (P = 0.121), and the ratio of D-xylose/3-O-methyl-D-glucose (P 
= 0.181) were normally distributed. However, D-xylose (P = 0.035) and sucrose (P = 
0.000) did not follow a normal distribution. 
The mean (± SD, range) percentage urinary recovery of intestinal permeability markers 
51Cr-EDTA, lactulose, and rhamnose was 6.3% (± 1.6%, 4.3–9.7%), 3.3% (± 1.1%, 
1.7–5.3%), and 25.5% (± 5.0%, 16.7–36.9%), respectively. The median (range) 
percentage urinary recovery of the intestinal absorptive function marker D-xylose 
was 40.3% (31.6–62.7%), and the mean (± SD, range) percentage urinary recovery 
of 3-O-methyl-D-glucose was 58.8% (± 11.0%, 40.1–87.8 %). The median (range) 
percentage urinary recovery for sucrose (gastric permeability marker) was 0.0% (0.0–
0.8%). 
The mean (± SD, range) urinary recovery ratio was 0.25 (± 0.06, 0.17–0.37) for 51Cr-
EDTA/rhamnose, 0.13 (± 0.04, 0.08–0.23) for lactulose/rhamnose, and 0.73 (± 0.09, 
0.60–0.90) for D-xylose /3-O-methyl-D-glucose. 
The correlation coefficients and significance levels for the biomarkers evaluated in study 
I are presented in Table 9. 
 
Results 
35
Table 8. Individual data on healthy male laboratory Beagles (study I), and the recovery of markers in urine after orogastric administration.
Dog
no.
51Cr-EDTA
% recovery
L
% recovery
R
% recovery
51Cr-EDTA/R
recovery ratio
L/R
recovery ratio
X
% recovery
G
% recovery
X/G
recovery ratio
S
% recovery
1 4.7 2.1 25.2 0.19 0.08 54.3 60.4 0.90 0
2 6.2 2.7 22.9 0.27 0.12 34.8 50.5 0.69 0.4
3 6.7 3.2 25.8 0.26 0.13 34.1 53.3 0.64 0.3
4 8.0 3.4 22.7 0.35 0.15 31.6 49.7 0.64 0.4
5 7.7 3.5 31.5 0.24 0.11 40.3 67.0 0.60 0.8
6 4.6 2.2 21.4 0.22 0.10 34.0 50.1 0.68 0.2
7 4.8 2.1 20.6 0.23 0.10 40.0 49.3 0.80 0
8 6.0 4.0 30.7 0.20 0.13 42.0 66.6 0.63 0
9 4.6 3.9 25.1 0.18 0.15 52.1 63.7 0.82 0
10 4.3 3.1 23.3 0.18 0.13 61.8 68.4 0.90 0
11 6.4 4.7 36.9 0.17 0.13 62.7 87.8 0.71 0
12 4.3 1.7 16.7 0.26 0.10 33.0 40.1 0.82 0.7
13 7.6 2.7 24.2 0.32 0.11 38.3 52.8 0.72 0
14 9.7 5.3 32.7 0.30 0.16 49.7 70.1 0.71 0
15 5.2 3.3 21.3 0.24 0.16 36.0 52.5 0.69 0
16 8.3 5.2 22.4 0.37 0.23 39.6 52.1 0.76 0
17 5.2 2.4 28.0 0.19 0.08 41.3 60.2 0.69 0
18 8.2 3.1 23.3 0.35 0.13 41.7 54.0 0.77 0
19 7.0 4.8 30.0 0.23 0.16 47.2 69.3 0.68 0
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Table 9. Correlation coefficients and their significance levels (P values) between the urinary percentage recoveries for the biomarkers. Modified from 
study I.
Lactulose Rhamnose 51Cr-EDTA/R L/R Xylose
3-O-methyl-
D-glucose X/G Sucrose
51Cr-EDTA 0.64** 0.40 0.73*** 0.51* -0.07 0.16 -0.47* 0.00
Lactulose 0.63*** 0.20 0.80*** 0.37 0.61*** -0.29 -0.25
Rhamnose -0.32 0.07 0.63*** 0.90*** -0.40 -0.21
51Cr-EDTA/R 0.50* 0.61*** -0.49* -0.21 0.29
L/R 0.13 0.10 -0.13 -0.26
Xylose 0.85 *** 0.38 0.67***
3-O-methyl-
D-glucose -0.07 -0.43
X/G -0.42
Correlations were calculated using Pearson’s or Spearman’s rank coefficients where appropriate. 
Significance levels are expressed as: *P < 0.05, **P < 0.01, and ***P < 0.001.
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5.2 Comparison between the 51Cr-EDTA test measured in blood and 
urine in healthy adult Beagles (II)
The mean levels of 51Cr-EDTA in serum progressively increased until reaching a peak, 
and thereafter declined gradually (Fig. 6). The peak of 51Cr-EDTA in serum took place 
within 5 hours after its oral administration in 41 of the 43 trials attempted (95%). 
The mean ± SD (range) percentage of the orally-administered 51Cr-EDTA in all the 
observations (n = 43) in urine after 6 hours was 14.07 ± 8.72% (3.81–34.18%), while 
percentage recoveries in serum from the blood samples taken at 2, 3, 4, 5, and 6 hours 
were 0.49 ± 0.45% (0.02–2.13%), 0.75 ± 0.52% (0.03–1.89%), 0.82 ± 0.57% (0.13–
2.21%), 0.70 ± 0.53% (0.12–1.99%), and 0.47 ± 0.44% (0.11–1.79%), respectively. 
The correlation coefficients between urine and the serum samples (n = 43) are presented 
in Table 10. The results indicate that better correlations were obtained by summing 
the recovery rates for multiple blood samples. Although excellent correlations were 
obtained by combining the results for only two blood samples taken at 3 and 5 hours (r 
= 0.95) or at 3 and 4 hours (r = 0.94), the sum of recoveries for 4 or more blood samples 
gave the best correlations with the urinary recovery (r = 0.97) after oral administration 
of the test solution. Furthermore, in the 6 dogs that underwent repeated testing, the 
correlation coefficients between urine and individual blood samples varied from -0.01 
to 0.91. Likewise, the combination of 4 and more blood samples produced correlation 
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Figure 6. Profile of the mean course of 51Cr-EDTA activity in serum during 6 h after its oral 
administration to dogs (n = 43).
Table 10. Correlation coefficients between urine and serum samples (n = 43) of percentage 
recoveries of 51Cr-EDTA after its oral administration to Beagles. Modified from study II.
% URINE
(0-6h)
% SERUM
Single samples
Two 
samples
Three 
samples
Four 
samples Five samples
2 h 3 h 4 h 5 h 6 h 3+4 h 3+5 h 3+4+5 h 2+3+4+5 h 2+3+4+5+6 h
Correlation 
coefficients
0.61 0.84 0.89 0.82 0.68 0.94 0.95 0.94 0.97 0.96
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coefficients that varied from 0.97 to 0.99, whereas with the combination of only two 
blood samples taken at 3 and 5, and at 3 and 4 hours, the correlation coefficient varied 
from 0.91 to 0.98.
5.3 Comparison between the 51Cr-EDTA blood test measured in serum 
and plasma in healthy adult Beagles (III)
The mean ± SD percentages of 51Cr-EDTA in serum and plasma after 3 h were 0.85 ± 
0.43% and 0.88 ± 0.49%, respectively, whereas the respective percentages in serum and 
plasma after 5 h were 0.78 ± 0.52% and 0.81 ± 0.51%. No significant differences were 
detected between the percentages of 51Cr-EDTA in serum and plasma samples at 3 and 
5 h (Fig. 7). In addition, statistically significant correlations were found between serum 
and plasma levels of 51Cr-EDTA at 3 h (R = 0.96, P < 0.0001), and at 5 h (R = 0.99, P < 
0.0001; Fig. 8). The combined correlation coefficient between the percentages from the 
serum and plasma samples was excellent (R = 0.98).
Figure 7. 51Cr-EDTA recovery percentages from serum (grey) and plasma (white) samples at 3 
and 5 h after ingestion. The horizontal line in the box is the median (50% percentile), and the 
upper and lower limits of the box indicate the 75% upper and 25% lower quartiles, respectively. 
The limits of the upper and lower vertical lines represent the maximum and minimum data values, 
respectively. No outliers were detected in the samples. Reprinted with permission from study III.
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Figure 8. Relationships between serum and plasma levels at 3 h (□ and discontinuous line) and 
5 h (● and continuous line) after ingestion of 51Cr-EDTA dissolved in water. Lines show the 
Pearson correlation (linear adjustment) at 3 h (R = 0.96, P < 0.0001, and at 5 h (R = 0.99, P < 
0.0001). Reprinted with permission from study III.
5.4 Comparison between 51Cr-EDTA and iohexol as permeability blood 
markers in healthy adult Beagles (IV)
The mean percentage recoveries in serum of 51Cr-EDTA and iohexol over the 6-h time 
course after simultaneous oral administration of both markers, and the significance of 
the difference in serum recovery between the two markers at each time point is shown 
in Table 11.
Figure 9 illustrates the mean (± SD) percentage recoveries of 51Cr-EDTA and iohexol 
at each time point, whereas Figure 10 displays the positive linear association between 
51Cr-EDTA and iohexol after analysis of all serum values from all dogs throughout the 
6-h time course. 
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Table 11. 51Cr-EDTA and iohexol mean recovery percentages in serum samples of seven healthy 
Beagle dogs after oral administration, and differences between both markers during the 6-h time 
course. Reprinted with permission from study IV.
Time
51Cr-EDTA 
(%) Iohexol (%)
Difference between
51Cr-EDTA and Iohexol
P-value
paired T-test
Hours Mean Mean Mean 95% CI
0.5 0.266 0.032 0.23 0.13-0.33 0.0012
1 0.306 0.048 0.26 0.18-0.34 0.0002
2 0.282 0.048 0.23 0.14-0.33 0.0010
3 0.182 0.033 0.15 0.05-0.11 0.0088
4 0.098 0.022 0.08 0.03-0.12 0.0060
5 0.067 0.013 0.06 0.03-0.08 0.0014
6 0.059 0.011 0.05 0.02-0.07 0.0031
Figure 9. Time course and percentage recovery in serum of 51Cr-EDTA and iohexol expressed as 
mean values ± SD after oral administration of both markers to seven healthy Beagle dogs. In A) 
the curves for both markers are shown on the same scale; in B) the curve for iohexol has been re-
scaled to aid in the visual comparison with 51Cr-EDTA. Reprinted with permission from study IV.
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Figure 10. Linear association (correlation and simple regression equation model) between the 
percentage recovery in serum of 51Cr-EDTA and iohexol at seven time points (between 0.5 and 
6 h) from all seven dogs. Discontinuous lines represent the 95% confidence intervals. Reprinted 
with permission from study IV.
5.5 Evaluation of iohexol as a permeability marker in healthy rats and in 
rats with DSS-induced inflammatory bowel disease (V)
The median percentage (%) (IQR) of iohexol in healthy rats was 0.54% (0.36–0.75%), 
whereas the respective value after DSS administration was 11.42% (5.58–15.37%). The 
median (IQR) iohexol/creatinine ratio was 0.05 (0.03–0.06) in healthy rats and 1.38 
(0.76–2.49) in rats with IBD. Nonparametric comparison of the urinary excretion of 
iohexol as well as the iohexol/creatinine ratio demonstrated statistically significant 
differences (P < 0.001) between healthy rats and those with ulcerative colitis. 
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Figure 11. Percentile plots of urinary iohexol before and after the induction of inflammatory 
bowel disease by adding 5% DSS to the drinking water of SD rats (n = 28) for seven days. The 
line in the box represents the median (50%); the lower line represents the 25% lower quartile, and 
the upper line represents the 75% upper quartile. The limits of the upper and lower vertical lines 
indicate the maximum and minimum data values, respectively. The separate asterisks indicate 
outliers. Modified with permission from study V.
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6. DISCUSSION 
6.1 Reference ranges and comparisons between the most relevant 
permeability markers in healthy adult Beagles (I)  
Because it is difficult to define an effective normal range of intestinal permeability 
that is common for all canine patients and breeds in both the veterinary clinical and 
biomedical research arenas, it has been necessary to determine a normal intestinal 
permeability index that is specific for each dog breed (Randell et al., 2001, Weber et al., 
2002). The novelty of this research was to report the 6-h percentage urinary recovery 
after oral administration of 51Cr-EDTA, lactulose, rhamnose, D-xylose, 3-O-methyl-D-
glucose, and sucrose in healthy adult male Beagle dogs housed in controlled laboratory 
conditions. It is well known that intrinsic differences exist between species in intestinal 
permeability related to the physical properties of the epithelium (Randell et al., 2001). 
Moreover, it has been determined that animal factors including breed, age, body size, 
sexual and health status, as well as environmental factors such as diet should be taken 
into account when defining normative ranges of intestinal permeability markers (Weber 
et al., 2002). However, these factors have largely been ignored in clinical practice and 
scientific reports using intestinal permeability tests in dogs. The overlooking of all such 
factors can certainly account for some of the variability observed in the normal recovery 
intervals for the markers in this species, and for the disparity observed in the results 
of some reports using permeability tests in dogs with enteropathies. This variability 
may be explained by the unconcerned use of pubertal and adult male and female dogs 
(intact and sterilized), which have been fed with different diet types (e.g. canned, dried 
or home-made diets), and by using apparently healthy dogs that could have been affected 
by subclinical intestinal disease or small intestinal bacterial overgrowth, as has been 
reported for Beagle dogs and humans affected with coeliac disease. (Delahunty and 
Hollander, 1987, Batt et al., 1992, Jezyk et al., 1992, Ferguson et al., 1993, Bijlsma et 
al., 1995, Kararli, 1995, Garden et al., 1997, Garden et al., 1998, Vaden et al., 2000, 
Randell et al., 2001, Weber et al., 2002, Allenspach et al., 2006, Kobayashi et al., 2007, 
Berghoff, 2011) 
In our studies using different intestinal permeability markers given simultaneously, 
the 6-h percentage urinary recovery for 51Cr-EDTA in healthy adult male Beagle dogs 
ranged from 4.3 to 9.7%, whereas the mean 24-h percentage urinary recovery of the 
radiolabeled chelate in clinically health dogs was previously reported to vary between 
2.3 and 17.3% (Hall et al., 1989). The 6-h urinary recovery ratio between lactulose and 
rhamnose in the healthy adult male Beagle dogs of our studies ranged between 0.08 and 
0.23. Reported results using healthy dogs of different breeds have shown the healthy 
ranges of lactulose/rhamnose to vary from 0.03 (Garden et al., 1997) to 0.42 (Weber 
et al., 2002), including 0.03–0.18 in Irish Setters (Garden et al., 1997), 0.19–0.34 in 
Greyhounds  (Randell et al., 2001), 0.07–0.26 in Viszlas (Randell et al., 2001), 0.08–0.34 
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in mixed-breed dogs (Randell et al., 2001), 0.14-0.21 in adult Miniature Poodles (Weber 
et al., 2002), 0.13–0.26 in adult Standard Schnauzers (Weber et al., 2002), 0.17–0.32 in 
adult Giant Schnauzers (Weber et al., 2002), 0.26–0.42 in adult Great Danes (Weber et 
al., 2002), and 0.05–0.15 in Beagles (Steiner et al., 2001a). 
For markers of intestinal absorptive function, the 6-h urinary recovery ratio of D-xylose 
to 3-O-methyl-D-glucose ranged from 0.60 to 0.90 in our healthy adult male laboratory 
Beagles, which was consistent with similar studies on a mixed group of Beagles (0.40–
0.59) (Steiner et al., 2000, Steiner et al., 2001b), and in other breeds, including adult 
Miniature Poodles (0.52–0.65) (Weber et al., 2002), adult Standard Schnauzers (0.51–
0.68) (Weber et al., 2002), adult Giant Schnauzers (0.54–0.62) (Weber et al., 2002), and 
adult Great Danes (0.56–0.62) (Weber et al., 2002). 
As expected taking into account the breed, age, body size, sexual and health status, and 
possibly dietary effects on intestinal permeability in dogs, the ranges of the intestinal 
permeability markers (i.e. 51Cr-EDTA, lactulose and rhamnose) for healthy adult male 
Beagle dogs used in our studies were considerably different from, but in agreement 
with, the results of other investigations that have used heterogeneous groups of clinically 
healthy dogs. Conversely, findings from the intestinal function markers (i.e. D-xylose, 
3-O-methyl-D-glucose) were in agreement with previous investigations suggesting that, 
in contrast to apparent morphological differences, the carrier-mediated mechanisms that 
allow intestinal absorption remain more similar between adult dogs of different breeds. 
In our studies, the simultaneous administration of multiple markers was considered not 
to affect the recovery of each individual marker, as has previously been shown in dogs. 
Therefore, it is unlikely that any of the probe markers used in our examinations interfered 
with the permeation or absorption of the other molecules. (Steiner et al., 2000, Vaden et 
al., 2000, Steiner et al., 2002, Weber et al., 2002)
6.2 51Cr-EDTA versus lactulose and sugar probes for intestinal 
permeability measurements (I)
Although 51Cr-EDTA and lactulose have markedly different physicochemical features, 
they have been regarded as equivalent intestinal permeability markers in humans and 
animals, including dogs. This is because of their similar molecular weight and cross-
sectional diameter, and also because the rate of permeation through the intestinal 
wall revealed a high corresponding rate between the two markers after simultaneous 
administration in trials on humans and cats. When the intestinal permeation of 51Cr-
EDTA and lactulose was analyzed after concurrent administration in humans and 
cats, both molecules showed a strong correlation when they were compared as single 
markers (humans: r = 0.98, P = 0.001; cats: r = 0.85, P = 0.03), or as ratios of both 
molecules against rhamnose (cats: r = 0.97, P = 0.002). (Maxton et al., 1986, Johnston 
et al., 2001)
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Nevertheless, our data from study I (Table 6) suggest that the correlation between the 
percentage urinary recovery of 51Cr-EDTA and lactulose after their concurrent oral 
administration in Beagle dogs is not as prominent as previously observed in humans and cats 
when compared as single markers (r = 0.64, P = 0.003), or as ratios to rhamnose (r = 0.50, 
P = 0.03). The lower correlation between these two markers in our dogs may be explained 
by the possible partial degradation of the sugar probes, such as lactulose by intestinal 
enzymes (hydrolization) or luminal bacteria (metabolization) of Beagles. However, a more 
likely reason for this disagreement is associated with intestinal breakdown of the sugar 
by intestinal resident bacteria, as it is well known that apparently healthy Beagles may be 
affected by small intestinal bacterial overgrowth, a dysbiotic condition that is consistent 
with intestinal degradation of saccharides such as lactulose. (Hall and Batt, 1991c, Batt et 
al., 1992, Hall and Batt, 1996, Riordan et al., 1997, Shen et al., 2009). 
Our findings of a lower correlation between the recovery of 51Cr-EDTA and lactulose 
after their concurrent administration in Beagles suggest that caution should be exercised 
when intestinal permeability tests are carried out using saccharides, because dogs 
suspected of having intestinal dysbiosis (e.g. any dog with enteropathy) may yield false 
negative results. It is generally accepted that 51Cr-EDTA is a more sensitive intestinal 
permeability marker than the sugar probes because of its biological inertness and its 
resistance to intestinal bacterial degradation. Because the low correlation between 51Cr-
EDTA and lactulose, it may be assumed that sugar probes may not be considered optimal 
markers to measure intestinal permeability in dogs, at least in Beagles.
No significant positive correlation was detected between the percentage urinary recovery 
of 51Cr-EDTA and other sugar markers such as rhamnose, D-xylose, 3-O-methyl-
D-glucose, and sucrose, which is consistent with current knowledge on the recovery 
rates after intestinal permeation of such markers. Interestingly, the correlation between 
rhamnose, a marker reflecting non-mediated diffusion throughout the small intestine, 
and 3-O-methyl-D-glucose, a molecule that is very efficiently absorbed across the small 
intestine via a specific carrier-mediated transport system, was very strong (r = 0.90, P 
= 0.000). This may indicate that both markers are absorbed in a parallel manner by the 
intact small bowel mucosa of healthy Beagles. Support for this suggestion is added by the 
lower correlation (r = 0.63, P = 0.004) between rhamnose and D-xylose, whose intestinal 
absorption mechanism is similar to that of 3-O-methyl-D-glucose (i.e. via a specific 
carrier-mediated transport system) but limited to the jejunal mucosa, thus resulting in a 
lower absorption rate of D-xylose than of 3-O-methyl-D-glucose in the small intestine.
6.3 A single marker versus a combination of two for intestinal 
permeability measurements (I) 
It has generally been assumed that the ratio of two molecules provides a more reliable 
index of intestinal damage and dysfunction than single markers alone. However, the 
correlation rates observed in our studies in healthy Beagles between the percentage 
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recoveries of single markers (51Cr-EDTA or lactulose) against their respective ratios to 
rhamnose (r = 0.73, P = 0.000, and r = 0.80, P = 0.000, respectively) suggest that the use 
of a single marker provides equivalent results to the use of a combination of two markers 
for assessing intestinal permeability in dogs. Furthermore, the analysis of one marker 
instead of two has practical and economic advantages.  
6.4 The 51Cr-EDTA blood test in Beagles (II, III)
To the best of our knowledge, the 51Cr-EDTA intestinal permeability test in blood has 
never been attempted in human or veterinary medicine, and our aim was to develop it 
using laboratory Beagle dogs. 
Findings from our studies indicate that it is possible to measure and calculate the 
percentage recovery of 51Cr-EDTA in the blood of Beagle dogs after oral ingestion of the 
probe molecule dissolved in water. The blood profile of the 6-h time course of 51Cr-EDTA 
showed equivalence with previous reports using 51Cr-EDTA as an intestinal permeability 
marker in the urine of healthy dogs. (Marks and Williams, 1998) Our results on the time 
course of 51Cr-EDTA in urine and blood over 6 hours provided further evidence that the 
absorption of 51Cr-EDTA across the canine intestine is more important during the first 
hours after its oral administration, and supports the proposed 6-h testing time as being 
more favorable than the 24-h test. The shorter testing time significantly increases the 
practicability of the test in dogs, increases the welfare of the subjects being housed in 
small metabolic cages for a more prolonged time, and allows the assessment of small 
intestinal permeability more specifically.  
The statistical analysis of the results for the 43 observations in study II revealed a 
strong correlation between the recovery of 51Cr-EDTA in urine and blood. Recovery 
rates determined for single blood samples correlated well with the cumulative 6-h urine 
recovery, especially when a blood sample was taken at 4 hours (r = 0.89) (Table 10). 
However, the correspondence between urine and blood was significantly better when 
results for individual blood samples were combined. The correlation coefficient between 
results in urine and multiple blood samples was highest when four blood samples were 
summed (r = 0.97), and remained excellent when only two blood samples taken at 3 and 
5 h (r = 0.95) or at 3 and 4 h (r = 0.94) were summed (Table 10). It was expected that the 
sum of percentages in sera would correlate better with urine than single blood samples, 
because the latter is measured at one point in time whereas the former more closely 
resembles the cumulative excretion of 51Cr-EDTA in urine. Additionally, the stability of 
these findings was confirmed by the results on the correlations between urine and sera 
from the 6 dogs that underwent intestinal permeability testing thrice.
The levels of 51Cr-EDTA in both serum and plasma after oral ingestion of the probe 
molecule in dogs were strongly correlated (Fig. 8). This demonstrates that the 51Cr-
EDTA intestinal permeability blood test in dogs can be equally performed on either 
serum or plasma samples, and supports the use of plasma when a small amount of blood 
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is collected from the patient. These correlations were further analyzed using the Bland–
Altman test, which revealed no differences in 51Cr-EDTA levels between serum and 
plasma samples. The regression line of differences versus means and 95% confidence 
intervals was additionally included, illustrating a linear regression between the 2-sample 
tests. Therefore, the intestinal permeability test measured in blood showed no differences 
in 51Cr-EDTA levels of serum or plasma, evidencing that there are no differences in the 
two methods used for assessing intestinal permeability in dogs.
6.5 Iohexol as a potential intestinal permeability marker in dogs (IV)
In study IV, a strong correlation including a clear linear association was detected 
between 51Cr-EDTA and iohexol during the 6-h time course in serum after concurrent 
oral administration of both markers, suggesting that they follow a similar mucosal 
permeability pathway across the intestinal wall.  The percentage serum recovery values 
of 51Cr-EDTA were significantly higher than iohexol at each time point, which may 
be explained by the lower molecular weight (359 Da) and the smaller cross-sectional 
diameter of 51Cr-EDTA (10.5 Å) compared to iohexol (821 Da and 12 Å, respectively). 
This led to a higher absorption rate across the gut mucosa and thus higher serum levels of 
51Cr-EDTA compared to iohexol (Hollander et al., 1988, Andersen et al., 1996, Andersen 
et al., 2001).  
These findings are consistent with previous reports comparing 51Cr-EDTA and iohexol 
in animal models and humans, and because 51Cr-EDTA and iohexol share similar 
physicochemical properties and follow a similar mucosal permeability pathway across 
the intestinal wall, it would be expected that the results obtained with their use in health 
and disease would be similar. 
Nevertheless, further studies are warranted using iohexol as an intestinal permeability 
blood marker in dogs under clinical conditions altering the gut mucosa to confirm the 
validity of the iohexol intestinal permeability blood test as a diagnostic tool for use in 
research and routine clinical practice.
Although additional investigations will need to test whether iohexol truly detects gut 
injury and qualifies as a permeability marker, these results provide promise for further 
testing using clinically affected dogs.
6.6 Preclinical evaluation of iohexol as intestinal permeability marker 
using a well-characterized experimental intestinal disease rat model 
(V)
Laboratory Sprague-Dawley rats were used to replace an experimental disease model 
potentially induced in dogs. This was planned and executed in accordance with the 
guiding principles of replacement of laboratory animal use, since the features and 
symptomatology of the intestinal disease condition could be reproduced in the rat, an 
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animal with lower neurophysiological development than dogs. (Russell and Burch, 
Finnish Government, 1985, Communities., 1986, Europe, 1986) 
As previously demonstrated in laboratory rats, our findings from study V provided 
further evidence that intestinal permeability may be assessed in Sprague-Dawley rats by 
measuring the cumulative urinary excretion of an orally-administered dose of iohexol, 
using a different test protocol aimed at improving the welfare of the test subjects. In our 
studies, increased intestinal permeability was reflected in a higher excretion of iohexol 
in urine due to a higher permeation rate of the probe across the damaged intestinal 
mucosa of animals with enteric abnormalities. In our laboratory Sprague-Dawley rats, 
the median 24-h urinary recovery after the oral administration of iohexol was 0.54% in 
healthy individuals, and 11.42% in rats with a well-characterized experimentally-induced 
inflammatory bowel disease, indicating significantly higher excretion of the contrast 
medium in rats with enteropathy. These findings were in agreement with the values 
reported by other research groups using iohexol in rats with experimental enteropathies, 
providing further support for the valid use of iohexol in detecting intestinal alterations 
in a rat model of inflammatory bowel disease. (Stordahl, 1988a, b, Stordahl and Laerum, 
1988a, b, Laerum et al., 1990, Solheim et al., 1991, Andersen et al., 1992, Andersen et 
al., 2001)
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7. CONCLUSIONS
1. Normative data were provided on the percentage urinary recovery after a 6-h oral 
administration of the gastrointestinal permeability and function markers 51Cr-
EDTA, lactulose, rhamnose, D-xylose, 3-O-methyl-D-glucose, and sucrose to 
healthy adult male laboratory Beagle dogs that were used and cared for under 
controlled laboratory conditions. This is the most commonly used breed in animal 
research and one of the most popular companion breeds worldwide (in the top 3 
list of the American Kennel Club for 2011). These data add to current knowledge 
on the normal gastrointestinal mucosal integrity and absorptive capacity for this 
dog breed, type, and environment. 
2. The correlation between the percentage urinary recovery of intestinal permeability 
markers 51Cr-EDTA and lactulose in healthy adult Beagles was not as prominent 
as previously reported for humans and cats. The reason for this discrepancy was 
not specifically investigated, but it is likely to be associated with the degradation 
of the sugar probe by intestinal resident bacteria. Further studies may be needed 
for full clarification, but caution should meanwhile be warranted when using and 
interpreting gastrointestinal permeability and function test results obtained using 
lactulose and other sugar probes. This is particularly the case in dogs suspected 
of having intestinal dysbiosis, such as Beagles or clinical patients affected with 
gastrointestinal disease.
3. It has been claimed that intestinal permeability results obtained by only using a 
single marker may be affected by non-mucosal factors during intestinal permeation. 
However, the percentage urinary recovery of 51Cr-EDTA and lactulose used as 
single intestinal permeability markers, and the ratio of these same molecules 
against rhamnose (51Cr-EDTA/rhamnose and lactulose/rhamnose, respectively), 
provided a strong and very significant correlation. This suggests that the use 
of a single marker may be sufficient and more practical for assessing intestinal 
permeability in healthy dogs, and the same is probably also true in dogs affected 
with an intestinal disorder.
4.  The 51Cr-EDTA permeability test in blood addresses the problems associated with 
urine collection in dogs, and obviates the laborious sample preparation that is 
required for the sugar probes. The blood approach based on the collection of at least 
two blood specimens gives results that are comparable with the 6-h cumulative 
urine test, and can thus provide a means of assessing intestinal permeability in 
dogs. Multiple blood sample collection (i.e. 3–5 samples) provides slightly better 
correlation results with the urine-based test than a single blood sample, and this 
would be therefore recommended when the test’s sensitivity is to be increased. 
Nevertheless, further studies are needed on dogs with intestinal disease in order 
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to define a cut-off value that would enable normal and abnormal individuals to be 
discriminated with more precision.
5. The use of plasma or whole blood during the 51Cr-EDTA intestinal permeability 
blood test may be preferable to the use of serum in certain patients in which 
a lower volume of blood sample is anticipated, such as in juvenile animals or 
miniature dog breed patients. It was concluded that the choice between serum or 
plasma when performing the 51Cr-EDTA intestinal permeability blood test in dogs 
is not relevant and is only one of convenience.
6. A clear relationship between serum levels of 51Cr-EDTA and iohexol was recorded 
when they were simultaneously administered, suggesting that both molecules 
behave similarly as blood markers in the assessment of intestinal permeability in 
dogs. 
7. The intestinal permeability test using iohexol in a laboratory rat model with a 
well-characterized experimentally-induced intestinal disease was able to clearly 
discriminate between healthy animals and rats with intestinal mucosal damage. 
8. Additional studies using iohexol as an intestinal permeability blood marker in 
dogs under clinical conditions, in which the gut mucosa is altered, are required to 
confirm the validity of the iohexol intestinal permeability blood test in dogs for 
future clinical and scientific use.
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